Iterum Therapeutics Ownership 2024 | Who Owns Iterum Therapeutics Now?


OverviewRevenueFinancialsChartTranscripts

Institutional Ownership

0.00%

Insider Ownership

1.81%

Retail Ownership

98.19%

Institutional Holders

1.00

Iterum Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC0.00%-66--76Jun 30, 2024
ANCORA ADVISORS, LLC----38-100.00%-Jun 30, 2024

Iterum Therapeutics's largest institutional shareholder is BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC, holding 0.00% of the company's total share outstanding, currently valued at $76.00. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC0.00%-66--76Jun 30, 2024
ANCORA ADVISORS, LLC----38-100.00%-Jun 30, 2024

The largest Iterum Therapeutics shareholder by % of total assets is BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC. The company owns 66.00 shares of Iterum Therapeutics (ITRM), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC0.00%-66--76Jun 30, 2024
ANCORA ADVISORS, LLC----38-100.00%-Jun 30, 2024

As of Jun 30 2024, Iterum Therapeutics's largest institutional buyer is BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC. The company purchased 0.00 stocks of ITRM, valued at $76.00.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ANCORA ADVISORS, LLC----38-100.00%-Jun 30, 2024
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC0.00%-66--76Jun 30, 2024

As of Jun 30 2024, Iterum Therapeutics's biggest institutional seller is ANCORA ADVISORS, LLC. The company sold -38.00 shares of ITRM, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ANCORA ADVISORS, LLC----38-100.00%-Jun 30, 2024

Iterum Therapeutics's largest sold out institutional shareholder by shares sold is ANCORA ADVISORS, LLC, sold -38.00 shares, valued at -, as of undefined.

Iterum Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
Destra Investment Trust0.00%783--Mar 31, 2024
Dimensional ETF Trust0.00%35,935--Jan 31, 2024

Iterum Therapeutics's largest mutual fund holder by % of total assets is "Destra Investment Trust", owning 783.00 shares, compromising 0.00% of its total assets.

Iterum Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Jun, 241-50.00%
31 Mar, 242-
31 Dec, 232-
30 Sep, 232-
30 Jun, 232-
31 Mar, 232-33.33%
31 Dec, 223-25.00%
30 Sep, 224-86.21%
30 Jun, 2229-
31 Mar, 2229-14.71%
31 Dec, 2134-
30 Sep, 2134-12.82%
30 Jun, 2139-13.33%
31 Mar, 2145136.84%
31 Dec, 201958.33%
30 Sep, 201220.00%
30 Jun, 2010-28.57%
31 Mar, 20147.69%
31 Dec, 1913-27.78%
30 Sep, 1918-5.26%
30 Jun, 1919-
31 Mar, 1919-13.64%
31 Dec, 182210.00%
30 Sep, 1820-16.67%
30 Jun, 1824-

As of 30 Jun 24, 1 institutions are holding Iterum Therapeutics's shares, representing a decrease of -50.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Jun, 2466-36.54%
31 Mar, 24104-
31 Dec, 23104-
30 Sep, 23104-
30 Jun, 23104-
31 Mar, 23104-69.77%
31 Dec, 22344-99.69%
30 Sep, 22110,950-98.11%
30 Jun, 225,880,69415.52%
31 Mar, 225,090,678-22.33%
31 Dec, 216,554,3107.65%
30 Sep, 216,088,689-46.92%
30 Jun, 2111,471,37944.15%
31 Mar, 217,958,11813.95%
31 Dec, 206,983,82440.38%
30 Sep, 204,974,883-19.23%
30 Jun, 206,159,402-12.46%
31 Mar, 207,036,339-0.43%
31 Dec, 197,066,43718.23%
30 Sep, 195,976,908-1.79%
30 Jun, 196,085,777-0.93%
31 Mar, 196,143,119-2.48%
31 Dec, 186,299,203-0.74%
30 Sep, 186,346,311-4.49%
30 Jun, 186,644,337-

Iterum Therapeutics (ITRM) has 66.00 shares outstanding as of 30 Jun 24, down -36.54% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Jun, 240.00%67750.00%
31 Mar, 240.00%123662.50%
31 Dec, 230.00%124075.00%
30 Sep, 230.00%122475.00%
30 Jun, 230.00%125000.00%
31 Mar, 230.00%10417.86%
31 Dec, 220.00%0.34%
30 Sep, 220.91%8.82%
30 Jun, 223.21%41.40%
31 Mar, 222.78%17.29%
31 Dec, 214.01%36.14%
30 Sep, 213.33%8.21%
30 Jun, 216.37%14.87%
31 Mar, 216.55%19.83%
31 Dec, 205.75%34.30%
30 Sep, 204.09%15.94%
30 Jun, 205.07%15.12%
31 Mar, 205.79%17.13%
31 Dec, 195.81%24.04%
30 Sep, 194.92%19.62%
30 Jun, 195.01%19.60%
31 Mar, 195.05%18.82%
31 Dec, 185.18%19.01%
30 Sep, 185.22%17.47%
30 Jun, 185.47%-

As of 30 Jun 24, Iterum Therapeutics is held by 0.00% institutional shareholders, representing a 67750.00% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Jun, 24--100.00%
31 Mar, 241-
31 Dec, 23--
30 Sep, 23--
30 Jun, 23--100.00%
31 Mar, 231-50.00%
31 Dec, 222-
30 Sep, 22--100.00%
30 Jun, 221137.50%
31 Mar, 228-27.27%
31 Dec, 2111-21.43%
30 Sep, 2114-26.32%
30 Jun, 2119-47.22%
31 Mar, 2136176.92%
31 Dec, 2013116.67%
30 Sep, 20650.00%
30 Jun, 204-33.33%
31 Mar, 20620.00%
31 Dec, 19566.67%
30 Sep, 19350.00%
30 Jun, 192100.00%
31 Mar, 191-75.00%
31 Dec, 184-20.00%
30 Sep, 185-79.17%
30 Jun, 1824-

- institutional shareholders have increased their position in ITRM stock as of 30 Jun 24 compared to 1 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Jun, 24--
31 Mar, 24--
31 Dec, 23--
30 Sep, 23--
30 Jun, 23--
31 Mar, 23--100.00%
31 Dec, 221-66.67%
30 Sep, 223-25.00%
30 Jun, 224-
31 Mar, 224-42.86%
31 Dec, 21716.67%
30 Sep, 216-25.00%
30 Jun, 218700.00%
31 Mar, 211-
31 Dec, 20--100.00%
30 Sep, 201-
30 Jun, 201-50.00%
31 Mar, 202100.00%
31 Dec, 191-87.50%
30 Sep, 198-27.27%
30 Jun, 1911-8.33%
31 Mar, 191271.43%
31 Dec, 187-12.50%
30 Sep, 188-
30 Jun, 18--

- institutional shareholders have reduced their position in ITRM stock as of 30 Jun 24 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Jun, 241-50.00%66-36.54%0.00%67750.00%--100.00%--
31 Mar, 242-104-0.00%123662.50%1---
31 Dec, 232-104-0.00%124075.00%----
30 Sep, 232-104-0.00%122475.00%----
30 Jun, 232-104-0.00%125000.00%--100.00%--
31 Mar, 232-33.33%104-69.77%0.00%10417.86%1-50.00%--100.00%
31 Dec, 223-25.00%344-99.69%0.00%0.34%2-1-66.67%
30 Sep, 224-86.21%110,950-98.11%0.91%8.82%--100.00%3-25.00%
30 Jun, 2229-5,880,69415.52%3.21%41.40%1137.50%4-
31 Mar, 2229-14.71%5,090,678-22.33%2.78%17.29%8-27.27%4-42.86%
31 Dec, 2134-6,554,3107.65%4.01%36.14%11-21.43%716.67%
30 Sep, 2134-12.82%6,088,689-46.92%3.33%8.21%14-26.32%6-25.00%
30 Jun, 2139-13.33%11,471,37944.15%6.37%14.87%19-47.22%8700.00%
31 Mar, 2145136.84%7,958,11813.95%6.55%19.83%36176.92%1-
31 Dec, 201958.33%6,983,82440.38%5.75%34.30%13116.67%--100.00%
30 Sep, 201220.00%4,974,883-19.23%4.09%15.94%650.00%1-
30 Jun, 2010-28.57%6,159,402-12.46%5.07%15.12%4-33.33%1-50.00%
31 Mar, 20147.69%7,036,339-0.43%5.79%17.13%620.00%2100.00%
31 Dec, 1913-27.78%7,066,43718.23%5.81%24.04%566.67%1-87.50%
30 Sep, 1918-5.26%5,976,908-1.79%4.92%19.62%350.00%8-27.27%
30 Jun, 1919-6,085,777-0.93%5.01%19.60%2100.00%11-8.33%
31 Mar, 1919-13.64%6,143,119-2.48%5.05%18.82%1-75.00%1271.43%
31 Dec, 182210.00%6,299,203-0.74%5.18%19.01%4-20.00%7-12.50%
30 Sep, 1820-16.67%6,346,311-4.49%5.22%17.47%5-79.17%8-
30 Jun, 1824-6,644,337-5.47%-24---

Iterum Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 27, 2023Dunne Michael W.director-P-PurchaseBuy25,000$1.40$35.00K113,754
Dec 19, 2023Dunne Michael W.director-P-PurchaseBuy10,000$1.84$18.44K88,754
Nov 27, 2023Dunne Michael W.director-P-PurchaseBuy20,000$2.03$40.69K78,754
Nov 20, 2023Fishman Corey N.director, officer Chief Executive OfficerP-PurchaseBuy10,000$1.59$15.86K54,449

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 27, 2023Dunne Michael W.director-P-PurchaseBuy25,000$1.40$35.00K113,754
Dec 19, 2023Dunne Michael W.director-P-PurchaseBuy10,000$1.84$18.44K88,754
Nov 27, 2023Dunne Michael W.director-P-PurchaseBuy20,000$2.03$40.69K78,754
Nov 20, 2023Fishman Corey N.director, officer Chief Executive OfficerP-PurchaseBuy10,000$1.59$15.86K54,449

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 12, 2024Dunne Michael W.director-M-ExemptSell212,494$0.61$129.62K-
Aug 12, 2024Fishman Corey N.director, officer Chief Executive OfficerM-ExemptSell165,226$0.61$100.79K-
Aug 12, 2024HUNT RONALDdirector-M-ExemptSell130,962$0.61$79.89K-
Dec 04, 2023Puttagunta Sailajaofficer Chief Medical OfficerM-ExemptSell8,333--16,666
Dec 04, 2023Puttagunta Sailajaofficer Chief Medical OfficerF-InKindSell2,933$2.12$6.22K10,369
Oct 02, 2023HUNT RONALDdirector-M-ExemptSell5,479---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 12, 2024Dunne Michael W.director-M-ExemptBuy106,247$1.21$128.56K220,001
Aug 12, 2024Dunne Michael W.director-M-ExemptBuy106,247$1.21$128.56K106,247
Aug 12, 2024Dunne Michael W.director-M-ExemptSell212,494$0.61$129.62K-
Aug 12, 2024Fishman Corey N.director, officer Chief Executive OfficerM-ExemptBuy82,613$1.21$99.96K137,062
Aug 12, 2024Fishman Corey N.director, officer Chief Executive OfficerM-ExemptBuy82,613$1.21$99.96K82,613
Aug 12, 2024Fishman Corey N.director, officer Chief Executive OfficerM-ExemptSell165,226$0.61$100.79K-
Aug 12, 2024HUNT RONALDdirector-M-ExemptBuy182,453$1.21$220.77K253,898
Aug 12, 2024HUNT RONALDdirector-M-ExemptBuy182,453$1.21$220.77K182,453
Aug 12, 2024HUNT RONALDdirector-M-ExemptBuy65,481$1.21$79.23K91,122
Aug 12, 2024HUNT RONALDdirector-M-ExemptBuy65,481$1.21$79.23K65,481
Aug 12, 2024HUNT RONALDdirector-M-ExemptSell130,962$0.61$79.89K-
Dec 27, 2023Dunne Michael W.director-P-PurchaseBuy25,000$1.40$35.00K113,754
Dec 19, 2023Dunne Michael W.director-P-PurchaseBuy10,000$1.84$18.44K88,754
Dec 04, 2023Puttagunta Sailajaofficer Chief Medical OfficerM-ExemptSell8,333--16,666
Dec 04, 2023Puttagunta Sailajaofficer Chief Medical OfficerA-AwardBuy8,333--13,302
Dec 04, 2023Puttagunta Sailajaofficer Chief Medical OfficerF-InKindSell2,933$2.12$6.22K10,369
Nov 27, 2023Dunne Michael W.director-P-PurchaseBuy20,000$2.03$40.69K78,754
Nov 20, 2023Fishman Corey N.director, officer Chief Executive OfficerP-PurchaseBuy10,000$1.59$15.86K54,449
Oct 02, 2023HUNT RONALDdirector-M-ExemptBuy5,479--14,346
Oct 02, 2023HUNT RONALDdirector-M-ExemptSell5,479---

The last insider sell of Iterum Therapeutics's stock was made by Dunne Michael W. on Aug 12 2024, selling 212,494 shares at $0.61 per share (valued at $129.62K). The last insider buy of ITRM was made by Dunne Michael W. on Dec 27 2023, buying 25,000 shares at $1.40 per share (worth $35.00K).

Iterum Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 202364150.00%
Q3 202322100.00%
Q2 202365120.00%
Q1 202376116.67%
Q4 202242200.00%
Q3 2022---
Q2 202294225.00%
Q1 202255100.00%
Q4 20212--
Q3 20211--
Q2 20218--
Q1 202197128.57%
Q4 20202--
Q3 20203560.00%
Q2 20202540.00%
Q1 202010--
Q2 2019137185.71%
Q1 20193--
Q4 20182--
Q3 20185--

6 total buy trades, and 4 total sell trades (buy/sell ratio of 1.50%) were made by Iterum Therapeutics's insiders, as of Q4 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 20233--
Q3 2023---
Q2 2023---
Q1 2023---
Q4 2022-1-
Q3 2022---
Q2 2022---
Q1 2022-2-
Q4 2021---
Q3 2021---
Q2 2021---
Q1 2021-5-
Q4 20202--
Q3 2020-1-
Q2 2020-2-
Q1 2020---
Q2 2019---
Q1 2019---
Q4 20182--
Q3 20185--

As of Q4 2023, Insider owners conducted 3 open market buy trades and 0 open market sell trades of Iterum Therapeutics's stocks.

Iterum Therapeutics Peer Ownership


TickerCompany
HOTHHoth Therapeutics, Inc.
CFRXContraFect Corporation
ADILAdial Pharmaceuticals, Inc.
AEZSAeterna Zentaris Inc.
OCUPOcuphire Pharma, Inc.
REVBRevelation Biosciences, Inc.
FBIOFortress Biotech, Inc.
CTXRCitius Pharmaceuticals, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
DFFNCervoMed Inc.
FWBIEntero Therapeutics, Inc.
DRMADermata Therapeutics, Inc.
JAGXJaguar Health, Inc.
EYENEyenovia, Inc.
VINCVincerx Pharma, Inc.
ONTXTraws Pharma, Inc.
ACSTAcasti Pharma Inc.
VRCAVerrica Pharmaceuticals Inc.
GRTXGalera Therapeutics, Inc.

ITRM Ownership FAQ


Iterum Therapeutics is owned by institutional shareholders (0.00%), insiders (1.81%), and public (98.19%). The largest institutional shareholder of Iterum Therapeutics is BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC (0.00% of total shares) and the top mutual fund owner is Destra Investment Trust (0.00% of total shares).

Iterum Therapeutics's major institutional shareholders are BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC, and ANCORA ADVISORS, LLC. The top five shareholders own together 0.00% of the company's share outstanding.

As of Jun 2024, there are 1 institutional shareholders of Iterum Therapeutics.

BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC owns 66 shares of Iterum Therapeutics, representing 0.00% of the company's total shares outstanding, valued at $76 (as of Jun 2024).

As of Jun 2024, ANCORA ADVISORS, LLC holds 0 shares of Iterum Therapeutics (ITRM), compromising 0% of the company, valued at $0.